Author: Customer Service

NOTICE OF EXERCISE OF MAKE WHOLE CALL OPTION MAXIMA GRUPE, UAB(the “Issuer”)1 €240,000,000 6.250 per cent. Notes due 2027(the “Notes”) (ISIN: XS2485155464) (Common Code: 248515546) 10 October 2025 We refer to the terms and conditions of the Notes (the “Conditions“). Capitalised terms used in this notice that are not otherwise defined have the meaning given to them in the Conditions. Pursuant to Condition 6(e) (Redemption at the Option of the Issuer (Make Whole)) of the Conditions, the Issuer hereby gives notice to the holders of the Notes that it has elected to redeem all the Notes on 27 October 2025 (the “Make Whole Optional Redemption Date“) at the Make Whole Redemption Price together with interest accrued to, but excluding, and unpaid to the Make Whole Optional Redemption Date. The Issuer...

-$300 million facility to fund Phase 1 of Panther Creek data center development with energization expected by YE 2026--On track to break ground on Panther Creek data center in Q4 2025- This news release constitutes a “designated news release” for the purposes of the Company’s second amended and restated prospectus supplement dated December 17, 2024, to its short form base shelf prospectus dated November 10, 2023. TORONTO, Ontario and NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq/TSX: BITF) (the “Company”), a North American energy and digital infrastructure company, has converted its previously announced private debt facility for up to $300 million from Macquarie Group’s Commodities and Global Markets business (“Macquarie”), to an up to $300 million project-specific financing facility for the development of its...

PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new healthcare focused institutional investors with the potential to raise up to $104.5 million in gross proceeds, including initial upfront funding of $16.5 million and up to an additional $88.0 million upon the potential cash exercise of accompanying warrants at the election of the...

BANGKOK, Oct. 10, 2025 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that Zacks Small-Cap Research (“Zacks”) has initiated equity research coverage on the Company. The full equity research report is available on the Zacks website here. About NewGenNewGenIVF Group is a tech-forward, diversified, multi-jurisdictional high-growth entity capitalizing on emerging opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through three strategic business divisions that leverage cutting-edge...

*** Limited places remain available for institutional investors for this previously announced Investor Access Event *** WASHINGTON, Oct. 10, 2025 (GLOBE NEWSWIRE) — ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it will host an Institutional Investor Access Event in South Africa from November 11-13, 2025. **There is also the possibility of adding an extra day to the trip and visiting the Renergen Virginia Gas Project on November 14th – please let us know if you are also interested in attending that day too. (subject to numbers)** All investors are invited to request a registration to attend the Institutional Investor Access Event. ASP...

SINGAPORE, Oct. 10, 2025 (GLOBE NEWSWIRE) — INNEOVA Holdings Limited (“INNEOVA Holdings” or the “Company”) (Nasdaq: INEO), through INNEOVA Engineering, a Singapore-based engineering solutions provider that maximizes equipment uptime, minimizes total ownership costs, and extends asset lifecycles through sustainable practices, today provided investors with an update on its hydrogen energy initiatives following the September 2025 signing of a Memorandum of Understanding with HyCee Pte. Ltd., a joint venture of GuoFu Hydrogen (“Jiangsu Guofu Hydrogen Energy Equipment Co. Ltd”) Since establishing the partnership, INNEOVA Engineering has advanced its strategic positioning as a pathfinder for hydrogen adoption in Singapore, aligning with the nation’s ambitious decarbonization roadmap. Singapore’s National Hydrogen Strategy,...

Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. (“EG BioMed”) one of the Company’s licensing partners for pancreatic and breast cancer detection and with 3D Global to develop treatment for eye disorders, has been accredited by the College of American Pathologists’ (CAP) Laboratory Accreditation Program for its CLIA-certified laboratory in Bothell, Washington (CLIA Certificate #50D2316600). CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, confirms that EG BioMed meets the highest standards of excellence in laboratory operations. Together with its existing...

MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. The closing of the offering is expected to occur on or about October 13, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company...

MUSCATINE, Iowa, Oct. 10, 2025 (GLOBE NEWSWIRE) — On August 4, 2025, HNI Corporation (NYSE: HNI; “HNI” or “the Corporation”) announced a definitive agreement to acquire Steelcase, Inc. (NYSE: SCS; “Steelcase”) in a cash and stock transaction (the “Acquisition”). In connection with the Acquisition, HNI previously announced the commencement of an offer to exchange any and all outstanding 5.125% Notes due 2029 (the “Existing Steelcase Notes”), as issued by Steelcase, for up to $450,000,000 aggregate principal amount of new notes to be issued by HNI (the “New HNI Notes”). HNI today announced that it has received consents from Eligible Holders (as defined herein) representing 77.83% in principal amount of the Existing Steelcase Notes pursuant to HNI’s previously announced (A) offer to exchange (the “Exchange Offer”) any and all...